Glucolipid metabolism

Glucolipid metabolism represents the highly integrated network of biochemical pathways responsible for the homeostasis of carbohydrates and fats in the body (National Center for Biotechnology Information [NCBI], 2023). It encompasses vital processes such as glycolysis, gluconeogenesis, lipogenesis, and beta-oxidation, which are coordinated by endocrine signals like insulin and glucagon to ensure energy availability and storage (StatPearls, 'Physiology, Metabolism', 2023). The liver, adipose tissue, and skeletal muscle act as central hubs for these activities, managing nutrient conversion and responding to shifts in energy demand (NIH, 'Metabolic Health', 2022). Chronic dysregulation of these pathways leads to 'glucolipotoxicity,' a state where excess glucose and fatty acids impair cellular function, contributing to the development of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) (Nature Reviews Endocrinology, 2021). While 'glucolipid metabolism' is not a single molecular target, it contains numerous validated therapeutic targets, including AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptors (PPARs), and sodium-glucose cotransporter 2 (SGLT2) (PubMed, PMCID: PMC7460235). Modulating these specific nodes allows for the pharmacological management of metabolic syndrome and its associated cardiovascular complications (Journal of Lipid Research, 2020).

Other names

Glucose and lipid metabolismMetabolic homeostasisGlucolipotoxicityGlycolipid metabolism

Drugs do not target 'glucolipid metabolism' as a single entity; instead, they modulate this process by targeting specific enzymes (e.g., HMG-CoA reductase, AMPK), receptors (e.g., PPARs, GLP-1 receptor), or transporters (e.g., SGLT2) involved in glucose and lipid handling.